vTv Therapeutics Inc. (VTVT)
Symbol Info
Listed Symbol VTVT
Name vTv Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $12,434,000
Latest Fiscal EPS $-0.72
Price Info
21 Day Moving Average $1.4494
21 Day EMA $1.499270
50 Day Moving Average $1.4006
50 Day EMA $1.446820
200 Day EMA $1.732750
200 Day Moving Average 1.773650
52 Week High $6.09
52 Week Low $0.75
52 Week Change $91.463400
Alpha 0.038747
Beta -3.5390
Standard Deviation 0.404546
R2 0.099872
Periods 50
Share Information
10 Day Average Volume 823,066
20 Day Average Volume 512,903
30 Day Average Volume 430,231
50 Day Average Volume 377,404
Outstanding Shares 56,557,367
Float Shares 56,426,253
Percent Float 99.77%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 79
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 339,069
Institute Holdings Percent 10.600000
Institute Sold Previous 3 Months 126,515
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 131,114
Price Change
7 Day Price Change $-0.045
7 Day Percent Change -2.79%
21 Day Price Change $0.2613001
21 Day Percent Change 19.97%
30 Day Price Change $0.2200000
30 Day Percent Change 16.30%
Month To Date Price Change $0.2613
Month To Date Percent 19.97%
90 Day Price Change $0.220000
90 Day Percent Change 16.30%
Quarter To Date $0.140000
Quarter To Date Percent 9.79%
180 Day Price Change $-0.27
180 Day Percent Change -14.67%
200 Day Price Change $-0.68
200 Day Percent Change -30.22%
Year To Date $-1.08
Year To Date Percent -40.75%
Profile
Description vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Details
Issue Type CS
Market Cap $88,795,066
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 56,557,367
CEO Stephen L. Holcombe
Employees 52
Last Audit UE
Classification
CIK 0001641489
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 4170 Mendenhall Oaks Parkway
High Point, NC 27265
Website http://www.vtvtherapeutics.com
Facisimile +1 336 841-0310
Telephone +1 336 841-0300
Email IR@vtvtherapeutics.com
Key Ratios
Profitability
EBIT Margin -99.4
EBITDA Margin -97.9
Pre-Tax Profit Margin -7,535.2
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $10,646,000
Revenue Per Share $0.3301
Revenue 3 Years $147.11
Revenue 5 Years $52.62
Valuation Measures
PE Ratio -
Enterprise Value $81,495,818
Price To Sales 4.756163
Price To Free Cash -3.1
PE High Last 5 Years -
Price To Book -
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -1.4
Financial Strength
Total Debt To Equity -
Int Coverage -3.9
Current Ratio 0.2
Leverage Ratio -0.2
Quick Ratio 0.2
Long Term Debt To Capital -
Assets
Receivables Turnover 2.2
Invoice Turnover -
Assets Turnover 0.60
Management Effectiveness
Return Assets -113.82
Return On Equity 19.03
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
VTVT
vTv Therap..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.